Camurus and Braeburn Pharmaceuticals announce positive Top-line results from long-term Phase 3 safety study of CAM2038

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder.

On 2 May 2017 Camurus (NASDAQ STO:CAMX) and Braeburn Pharmaceuticals announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder.